CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules
CBD Life Sciences Inc. (CBDL) has announced its entry into the functional mushroom market with the launch of Mushroom Powder Capsules. The product combines five medicinal mushrooms: Lion's Mane, Cordyceps, Reishi, Maitake, and Turkey Tail, targeting cognitive enhancement, immune support, and overall wellness.
The company aims to capitalize on the growing functional mushroom market, which is projected to exceed $19 billion by 2030 with a 9.1% CAGR. The capsules will be distributed through existing direct-to-consumer e-commerce channels and select retail partners, with plans for expansion.
CEO Lisa Nelson states this launch represents a strategic expansion beyond CBD products, positioning CBDL to tap into new revenue streams in the natural health sector. The company plans aggressive marketing and strategic partnerships to establish itself as a category leader in the functional mushroom space.
CBD Life Sciences Inc. (CBDL) ha annunciato il suo ingresso nel mercato dei funghi funzionali con il lancio delle Capsule di Polvere di Fungo. Il prodotto combina cinque funghi medicinali: Coda di Leone, Cordyceps, Reishi, Maitake e Coda di Tacchino, mirati a migliorare le funzioni cognitive, supportare il sistema immunitario e promuovere il benessere generale.
L'azienda punta a capitalizzare il crescente mercato dei funghi funzionali, che si prevede supererà i 19 miliardi di dollari entro il 2030 con un CAGR del 9,1%. Le capsule saranno distribuite attraverso i canali di e-commerce esistenti e partner selezionati al dettaglio, con piani di espansione.
Il CEO Lisa Nelson afferma che questo lancio rappresenta un'espansione strategica oltre i prodotti a base di CBD, posizionando CBDL per accedere a nuove fonti di reddito nel settore della salute naturale. L'azienda prevede un marketing aggressivo e partnership strategiche per affermarsi come leader di categoria nel settore dei funghi funzionali.
CBD Life Sciences Inc. (CBDL) ha anunciado su entrada en el mercado de los hongos funcionales con el lanzamiento de las Cápsulas de Polvo de Hongo. El producto combina cinco hongos medicinales: Melena de león, Cordyceps, Reishi, Maitake y Cola de pavo, con el objetivo de mejorar la cognición, apoyar el sistema inmunológico y promover el bienestar general.
La empresa busca capitalizar el creciente mercado de los hongos funcionales, que se proyecta que superará los 19 mil millones de dólares para 2030 con un CAGR del 9,1%. Las cápsulas se distribuirán a través de canales de comercio electrónico directo al consumidor existentes y socios minoristas seleccionados, con planes de expansión.
La CEO Lisa Nelson afirma que este lanzamiento representa una expansión estratégica más allá de los productos de CBD, posicionando a CBDL para acceder a nuevas fuentes de ingresos en el sector de la salud natural. La empresa planea un marketing agresivo y asociaciones estratégicas para establecerse como líder de categoría en el espacio de los hongos funcionales.
CBD Life Sciences Inc. (CBDL)는 기능성 버섯 시장에 진입하며 버섯 가루 캡슐을 출시한다고 발표했습니다. 이 제품은 사자갈기, 코르디셉스, 영지, 마이타케, 칠면조꼬리 등 다섯 가지 약용 버섯을 결합하여 인지 기능 향상, 면역 지원 및 전반적인 웰빙을 목표로 하고 있습니다.
회사는 2030년까지 190억 달러를 초과할 것으로 예상되는 성장하는 기능성 버섯 시장을 활용할 계획입니다. 캡슐은 기존의 직접 소비자 전자상거래 채널과 선택된 소매 파트너를 통해 유통되며, 확장 계획이 있습니다.
CEO 리사 넬슨은 이번 출시가 CBD 제품을 넘어서는 전략적 확장을 의미하며, CBDL이 자연 건강 분야에서 새로운 수익원을 확보할 수 있는 위치에 놓이게 될 것이라고 말했습니다. 회사는 기능성 버섯 분야에서 카테고리 리더로 자리 잡기 위해 공격적인 마케팅과 전략적 파트너십을 계획하고 있습니다.
CBD Life Sciences Inc. (CBDL) a annoncé son entrée sur le marché des champignons fonctionnels avec le lancement des Capsules de Poudre de Champignon. Le produit combine cinq champignons médicinaux : Crinière de lion, Cordyceps, Reishi, Maitake et Queue de dinde, visant à améliorer les fonctions cognitives, soutenir le système immunitaire et promouvoir le bien-être général.
La société vise à tirer parti du marché croissant des champignons fonctionnels, qui devrait dépasser 19 milliards de dollars d'ici 2030 avec un TAC de 9,1%. Les capsules seront distribuées via des canaux de commerce électronique directs existants et des partenaires de vente au détail sélectionnés, avec des plans d'expansion.
La PDG Lisa Nelson déclare que ce lancement représente une expansion stratégique au-delà des produits à base de CBD, positionnant CBDL pour accéder à de nouvelles sources de revenus dans le secteur de la santé naturelle. L'entreprise prévoit un marketing agressif et des partenariats stratégiques pour s'établir comme un leader de catégorie dans le domaine des champignons fonctionnels.
CBD Life Sciences Inc. (CBDL) hat seinen Eintritt in den Markt für funktionale Pilze mit der Einführung von Pilzpulverkapseln angekündigt. Das Produkt kombiniert fünf medizinische Pilze: Löwenmähne, Cordyceps, Reishi, Maitake und Truthahn-Schweif, die auf kognitive Verbesserung, Unterstützung des Immunsystems und allgemeines Wohlbefinden abzielen.
Das Unternehmen beabsichtigt, von dem wachsenden Markt für funktionale Pilze zu profitieren, der voraussichtlich bis 2030 über 19 Milliarden Dollar überschreiten wird, mit einer CAGR von 9,1%. Die Kapseln werden über bestehende Direktvertriebs-E-Commerce-Kanäle und ausgewählte Einzelhandelspartner vertrieben, mit Plänen zur Expansion.
CEO Lisa Nelson erklärt, dass dieser Launch eine strategische Erweiterung über CBD-Produkte hinaus darstellt und CBDL in die Lage versetzt, neue Einnahmequellen im Bereich der natürlichen Gesundheit zu erschließen. Das Unternehmen plant aggressive Marketingstrategien und strategische Partnerschaften, um sich als Marktführer im Bereich der funktionalen Pilze zu etablieren.
- Entry into fast-growing functional mushroom market ($19B by 2030)
- Diversification beyond CBD products into new revenue streams
- Established distribution channels already in place
- Multiple sales channels: direct-to-consumer and retail partnerships
- Entering highly competitive wellness supplement market
- No specific revenue projections or sales targets provided
- No mention of production capacity or supply chain details
The Global Functional Mushroom Market is Set to Surpass
SCOTTSDALE, ARIZONA / ACCESS Newswire / February 26, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making a bold move into the multi-billion-dollar functional mushroom market with the official launch of its Mushroom Powder Capsules-a powerful, all-natural supplement designed to elevate brain function, enhance energy, boost immunity, and optimize overall wellness.
This premium formulation combines five of the most researched and revered medicinal mushrooms:
Lion's Mane - Known for its neuroprotective properties, enhances cognitive function, memory, and focus.
Cordyceps - Increases stamina, improves athletic performance, and supports lung function.
Reishi - Helps reduce stress, promotes better sleep, and strengthens the immune system.
Maitake - Supports metabolic health and helps regulate blood sugar levels.
Turkey Tail - Packed with antioxidants and polysaccharides that fortify gut health and boost immunity.
With scientific studies confirming the vast health benefits of these mushrooms, CBDL is positioning itself at the forefront of the natural health revolution. The global demand for functional mushrooms has skyrocketed due to their ability to combat stress, enhance brain power, and promote longevity-aligning perfectly with consumer trends toward holistic wellness and plant-based supplementation.
A Massive Revenue Opportunity
By launching into the functional mushroom industry, CBDL is tapping into a market projected to exceed
CBDL's Mushroom Powder Capsules will be available through its existing sales channels, including direct-to-consumer e-commerce and select retail partners, with further distribution expansion planned as demand grows.
"This launch marks a pivotal moment for CBDL as we expand beyond CBD and into the booming functional mushroom sector," said Lisa Nelson, CEO of CBD Life Sciences Inc. "Our goal is to provide top-tier, science-backed natural solutions that enhance everyday health while capitalizing on one of the fastest-growing wellness trends in the world."
CBDL is committed to aggressive marketing, expanding its direct sales reach, and forming strategic partnerships to position its Mushroom Powder Capsules as a category leader. With consumer interest surging and scientific validation mounting, CBDL's foray into functional mushrooms represents not just an innovative product launch-but a major step toward long-term profitability and market dominance.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC:CBDL) is a leading innovator in the CBD and natural health industry, dedicated to developing high-quality, science-backed products that enhance wellness and vitality. With a growing portfolio spanning CBD topicals, edibles, and now functional mushrooms, CBDL continues to push boundaries in holistic health solutions.
For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences, Inc.
Related Images
View the original press release on ACCESS Newswire
FAQ
What are the 5 mushroom types in CBDL's new capsule product?
What is the projected market size for functional mushrooms by 2030?
How will CBDL distribute its new mushroom capsules?
What health benefits do CBDL's mushroom capsules target?
